23andMe Stock Soars 174% On Regeneron Acquisition Deal

(RTTNews) - 23andMe Holding Co. (MEHCQ) surged 163.33 percent to $2.37 on Monday after announcing a definitive agreement to sell substantially all of its assets to Regeneron Pharmaceuticals for $256 million.

The stock opened at $1.71 and traded between $1.67 and $2.52 on the OTC Markets. Volume reached 1.11 million shares, below the average of 4.08 million. MEHCQ now trades within a 52-week range of $0.47 to $12.32.

The deal includes 23andMe's Personal Genome Service, Total Health, and Research Services business lines but excludes its Lemonaid Health subsidiary, which will be wound down.